The therapeutic use of the newer JAK2 inhibitors also needs to be broadened by the FDA beyond PMF to meet the needs of chronic-phase PV and ET patients who are either intolerant or refractory to ruxolitinib, which itself can promote RAS mutations [186]. The gene discussed is JAK2; the disease is essential thrombocythemia.